Cancer and neoplasms
A PHASE I, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7566802 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (GO44431)
This is a first-in-human Phase I, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumour activity of RO7566802 as a single agent and in combination with atezolizumab in patients with locally advanced, recurrent, or metastatic incurable solid tumour malignancies.
The study consists of a screening period of up to 28 days, a treatment period, a minimum follow-up period of 90 days after treatment, and survival follow-up.
Patients will be enrolled in two stages: a ...
GO TO STUDY